Home » Topics » Regulatory » EMA

EMA
RSS

EMA's CHMP recommends approval of Amyvid

Oct. 22, 2012

CHMP recommends Abbott's Humira in pediatric Crohn's disease

Oct. 22, 2012

Tresiba and Ryzodeg receive positive CHMP opinions

Oct. 22, 2012

CHMP recommends Bayer's anticoagulant for additional use

Oct. 22, 2012

EMA committee issues opinion on Qsiva

Oct. 19, 2012

EMA accepts masitinib MAA for review

Oct. 8, 2012

MAA for ceftobiprole in pneumonia accepted for review under E.U. decentralized procedure

Oct. 8, 2012

EMA determines Sufentanil NanoTab PCA System eligible for centralized review

Oct. 5, 2012

Ariad completes rolling NDA submission for ponatinib

Oct. 1, 2012

EMA recommends approval of ingenol mebutate for actinic keratosis

Sep. 28, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...